Securing US Food and Drug Administration approval for its CHS-201 biosimilar Lucentis (ranibizumab) candidate will make a $50m loan payment available to Coherus BioSciences, Inc., under a broader $300m credit facility agreed with investment funds managed by Pharmakon Advisors.
The US biotech – which has disclosed the name Cimerli for its biosimilar Lucentis candidate during the virtual 40th Annual J.P. Morgan Health Care Conference – has an FDA action date for its ophthalmology biosimilar candidate in August 2022
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?